



Medicine Supply Notification

MSN/2026/044

Lansoprazole 15mg and 30mg orodispersible tablets

Tier 2 – medium impact*

Date of issue: 09/09/2026

Link: [Medicines Supply Tool](#)

Summary

- Lansoprazole 15mg and 30mg orodispersible tablets are in limited supply until early January 2027.
- Lansoprazole 15mg and 30mg gastro-resistant capsules remain available and can support increased demand.
- Alternative proton pump inhibitors remain available.
- Serious Shortage Protocols (SSPs) for lansoprazole 15mg and 30mg orodispersible tablets were issued on 9 September 2026 which allows community pharmacists to limit supply to one month.

Actions Required

Where supplies of lansoprazole 15mg and 30mg orodispersible tablets are available, community pharmacists and dispensing doctors should:

- consider limiting supply to one month of supply in accordance with SSP088 and SSP089 for eligible patients presenting with a prescription for more than one month's supply of lansoprazole 15mg and 30mg orodispersible tablets (see Supporting information).

Where supplies of lansoprazole 15mg and 30mg orodispersible tablets are unavailable clinicians should;

- review ongoing need and deprescribe where appropriate;
- where treatment is still required, consider prescribing lansoprazole gastro-resistant capsules taking into account patient-specific needs and local prescribing formularies; it may be worth noting that some lansoprazole capsules can be opened within license and used by patients who have swallowing difficulties (please refer to the SmPC of the specific product);
- if the above is not suitable, consider prescribing an alternative proton pump inhibitor, taking into account age, indication, dose, ability to swallow, product-specific licensing, drug interactions, excipients, storage requirements and local prescribing formularies (see Supporting information);
- consider reserving remaining supplies of lansoprazole orodispersible tablets for patients who cannot be switched to an alternative lansoprazole formulation (e.g. due to sensory issues, inability to follow administration instructions, or enteral feeding tubes in critical care), and for patients with clinically significant drug interactions with alternative proton pump inhibitors (e.g. clopidogrel) who cannot be switched to an alternative lansoprazole formulation.

Supporting information

Clinical Information

Prescribers should consult local prescribing formularies when considering the below additional advice if considering alternative PPIs:

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Paediatric patients prescribed clopidogrel can be prescribed lansoprazole orodispersible tablets or oral suspension (where available) according to local guidelines.

Paediatric patients under 1 year who use enteral feeding tubes can be prescribed omeprazole oral suspension.

Paediatric patients under 1 year who do not use enteral feeding tubes can be prescribed omeprazole oral suspension or omeprazole gastro-resistant dispersible tablets (off-label in under 1 year) taking into account their weight and the dose required. Dispersible tablet doses should be rounded to the nearest half tablet.

Paediatric patients between 1 to 18 years who use enteral feeding tubes can be prescribed omeprazole oral suspension, omeprazole gastro-resistant dispersible tablets or esomeprazole gastro-resistant granules taking into account their weight and size of the enteral feeding tube.

Paediatric patients between 1 to 18 years who do not use enteral feeding tubes can be prescribed omeprazole gastro-resistant dispersible tablets/capsules, omeprazole gastro-resistant tablets/capsules, lansoprazole gastro-resistant capsules (off-label in patients under 18 years) or esomeprazole gastro-resistant tablets/capsules (off-label in patients under 12 years), taking into account their ability to swallow solid dosage forms. Doses should be rounded up to the nearest tablet or capsule. Tablets may be dispersed in water and capsules opened and contents dispersed in water prior to administration - see individual manufacturer's product information for details.

Adult patients over 18 years old who use enteral feeding tubes can be prescribed most brands of omeprazole gastro-resistant dispersible tablets, most brands of esomeprazole gastro-resistant tablets and some brands of lansoprazole gastro-resistant capsules. Lansoprazole orodispersible tablets should be reserved for patients with enteral feeding tubes in critical care as well as those receiving medications with clinically significant interactions with alternative proton pump inhibitors e.g. clopidogrel.

Adult patients over 18 years old who do not use enteral feeding tubes can be prescribed omeprazole gastro-resistant dispersible tablets/gastro-resistant tablets/capsules, lansoprazole gastro-resistant capsules, esomeprazole gastro-resistant tablets/capsules, pantoprazole gastro-resistant tablets or rabeprazole gastro-resistant tablets where the patient is able to swallow solid oral dosage forms. For patients unable to swallow solid oral dosage forms, omeprazole gastro-resistant dispersible tablets and capsules, esomeprazole gastro-resistant tablets and granules, and some brands of esomeprazole capsules and lansoprazole capsules may be dispersed in water prior to administration. See [Specialist Pharmacy Service PPI suggestions for adults with swallowing difficulties](#) or individual manufacturers' product information for details.

[Links to further information](#)

[BNF - Lansoprazole](#)

[SmPC - Lansoprazole](#)

[SmPC - Omeprazole](#)

[SmPC - Esomeprazole](#)

[Specialist Pharmacy Service - PPI suggestions for adults with swallowing difficulties](#)

[NICE clinical guidance on GORD and dyspepsia in adults](#)

[Serious Shortage Protocols \(SSPs\) | NHSBSA](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.